Literature DB >> 9754730

Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs.

M Wøjdemann1, A Wettergren, B Hartmann, J J Holst.   

Abstract

BACKGROUND: Glucagon-like peptide-2 is formed from proglucagon in the intestinal L-cells and is secreted postprandially in parallel with the insulinotropic hormone GLP-1 (glucagon-like peptide-1), which in addition acts to inhibit gastric motility (enterogastrone effect) by inhibiting central parasympathetic outflow. GLP-2 has no effect on the endocrine pancreas. We here tested the hypothesis that GLP-2 acts as an enterogastrone.
METHODS: Fourteen anesthetized pigs with their splanchnic nerves cut were subjected to insulin hypoglycemia, and force transducers were sutured to the antrum to record motility. GLP-2 was infused intravenously in doses from 1 to 6 pmol/kg/min after the onset of antral motility in response to hypoglycemia.
RESULTS: Insulin hypoglycemia invariably and greatly increased the frequency and amplitude of antral phasic contractions. Infusions of GLP-2 dose dependently (1-6 pmol/kg/min) inhibited antral motility. At 2 pmol/kg/min, resulting in plasma GLP-2 concentrations of 102.5+/-19 pmol/l (normal postprandial range, 30-82 pmol/l), the motility index was inhibited by 91%+/-14%.
CONCLUSIONS: Both of the intestinal glucagon-like peptides may operate as hormonal transmitters of the ileal brake effect.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9754730     DOI: 10.1080/00365529850171486

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  38 in total

Review 1.  Gut adaptation and the glucagon-like peptides.

Authors:  D J Drucker
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

Review 2.  Enhancing bowel adaptation in short bowel syndrome.

Authors:  Palle Bekker Jeppesen; Per Brobech Mortensen
Journal:  Curr Gastroenterol Rep       Date:  2002-08

3.  Differential action of TGR5 agonists on GLP-2 secretion and promotion of intestinal adaptation in a piglet short bowel model.

Authors:  Sen Lin; Barbara Stoll; Jason Robinson; Jose J Pastor; Juan C Marini; Ignacio R Ipharraguerre; Bolette Hartmann; Jens J Holst; Stephanie Cruz; Patricio Lau; Oluyinka Olutoye; Zhengfeng Fang; Douglas G Burrin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-03-28       Impact factor: 4.052

Review 4.  Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation.

Authors:  G-R Martin; P-L Beck; D-L Sigalet
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

5.  Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.

Authors:  P B Jeppesen; E L Sanguinetti; A Buchman; L Howard; J S Scolapio; T R Ziegler; J Gregory; K A Tappenden; J Holst; P B Mortensen
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

6.  GLP-2 receptor in POMC neurons suppresses feeding behavior and gastric motility.

Authors:  Xinfu Guan; Xuemei Shi; Xiaojie Li; Benny Chang; Yi Wang; Depei Li; Lawrence Chan
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-07-24       Impact factor: 4.310

Review 7.  The gut and food intake: an update for surgeons.

Authors:  E Näslund; P M Hellström; J G Kral
Journal:  J Gastrointest Surg       Date:  2001 Sep-Oct       Impact factor: 3.452

8.  Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice.

Authors:  J Thulesen; B Hartmann; K J Hare; H Kissow; C Ørskov; J J Holst; S S Poulsen
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

9.  Supplementing monosodium glutamate to partial enteral nutrition slows gastric emptying in preterm pigs(1-3).

Authors:  Caroline Bauchart-Thevret; Barbara Stoll; Nancy M Benight; Oluyinka Olutoye; David Lazar; Douglas G Burrin
Journal:  J Nutr       Date:  2013-02-27       Impact factor: 4.798

10.  Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function.

Authors:  P B Jeppesen; P Lund; I B Gottschalck; H B Nielsen; J J Holst; J Mortensen; S S Poulsen; B Quistorff; P B Mortensen
Journal:  Gastroenterol Res Pract       Date:  2009-08-20       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.